The invention provides methods of treating a bacterial infection in a mammal comprising administering to the mammal a substituted bicyclic heteroaromatic ring compound of formula I: wherein two of X.sub.1 to X.sub.8 are N and the remaining of X.sub.1 to X.sub.8 are CH; or a pharmaceutically acceptable salt thereof, as well as novel compounds of formula I and salts thereof and pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. ##STR00001##

The present invention relates to compounds that have ultraviolet light absorbing properties, and which can also have mesogenic properties. The present invention also relates to compositions that include one or more such compounds, and to articles of manufacture that include one or more such compounds, such as optical elements that include an optical substrate and a layer that includes at least one compound of the present invention.

An organic compound represented by Chemical Formula 1, an organic optoelectric device including the organic compound, and a display device including the organic optoelectric device are disclosed.

An organic compound represented by Chemical Formula 1, an organic optoelectric device including the organic compound, and a display device including the organic optoelectric device are disclosed.

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula:

##STR00001##

The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.

The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.

Provided is a heterocyclic compound of Chemical Formula 1: ##STR00001##
where L.sub.1 is a single bond or a substituted or unsubstituted C.sub.6-60 arylene; L.sub.2 is a single bond, a substituted or unsubstituted C.sub.6-60 arylene, or a substituted or unsubstituted C.sub.5-60 heteroarylene, and Ar.sub.1 is one of the following Chemical Formulas 2, 3, 4, or 5: ##STR00002##
and an organic light emitting device including the same.

Provided is a heterocyclic compound of Chemical Formula 1: ##STR00001##
where L.sub.1 is a single bond or a substituted or unsubstituted C.sub.6-60 arylene; L.sub.2 is a single bond, a substituted or unsubstituted C.sub.6-60 arylene, or a substituted or unsubstituted C.sub.5-60 heteroarylene, and Ar.sub.1 is one of the following Chemical Formulas 2, 3, 4, or 5: ##STR00002##
and an organic light emitting device including the same.

A series of substituted heteroaromatic compounds containing two fused six-membered rings, tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.